

GENTOURINARY

CHELSEA HOTEL, TORONTO, ON
 ROOM: WREN
 SATURDAY APRIL 28TH, 2018, 8:00 AM – 3:00 PM

CHAIR: K. CHI
 SENIOR INVESTIGATOR: FRANCISCO VERA-BADILLO
 STUDY COORDINATORS: ALEXANDER MONTENEGRO & PAUL STOS
 (03:00 PM – 04:00 PM TRIAL DEVELOPMENT GROUP – CLOSED)

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To interpret and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials or its collaborators.
- To provide a learning environment supportive to new investigators.
- To interpret and apply new clinical trial methodologies in the field of clinical research in Canada

8:00 am	WELCOME	K. Chi
8:05 am	OPEN CUOG/CURC TRIALS	
	PRIME MAST Hypothermia RCC LIGAND TITAN ATLAS	N. Usmani M. Kenk I. Cagiannos M. Kenk K.Chi K.Chi
8:45 am	Discussion of opportunities to enhance correlative science activity in CCTG GU trials	D. Berman
9:00 am	Plenary Presentation: Circulating tumor DNA as a biomarker: opportunities and challenges Dr. Alex Wyatt	
	CCTG Lead OPEN TRIALS	
10:00 am	IND.223: A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer	K. Chi
	IND.232: A Phase II Study of Durvalumab (Medi4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer	S. Hotte

continued on next page ...

	IND.234: Prostate Cancer Biomarker Enrichment and Treatment	K. Chi
	Selection (PC_BETS) Study - Master Screening Protocol	
	PR.19: A randomized phase II trial evaluating treatment outcome, acute and long-term toxicity of High Dose Rate Brachytherapy (HDRB) and Low Dose Rate Brachytherapy (LDRB) as monotherapy in localized prostate cancer.	G. Morton/ E. Vigneault
	Phase II basket trial PM1/CAPTUR (<i>Canadian Profiling and Targeted agent Utilization</i>)	S. Hotte
	CCTG Lead CLOSED TRIALS	
10:25 am	BL.12 Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel in Second Line Metastatic Urothelial Carcinoma	K. Sridhar
	CCTG InterGroup OPEN TRIALS	
10:40 am	REC.3/PAPMET A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors Cabozantinib, Crizotinib and Savolitinib versus Sunitinib in Metastatic Papillary Renal Carcinoma.	M. Ong
	BLC.4 (SWOG S1605): Phase II Trial of Atezolizumab (NSC #783608) in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.	W. Kassouf
	CCTG InterGroup CLOSED TRIALS	
10:50 am	BLC.1/SWOG S1011 Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer	W. Kassouf
	PR.13/RADICALS/MRC PR.10 Radiotherapy and Androgen Deprivation In Combination After Local Surgery	W. Parulekar
	PRC.4/Alliance A031201 Phase III Enzalutamide + Abiraterone in castration resistant metastatic prostate cancer	K.Chi
	PR.17/ANZUP 1304- ENZAMET Phase III testosterone suppression with or without Enzalutamide in first line metastatic prostate cancer	S. North
	PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen Deprivation prior to RP v.s. RP only	K.Chi

continued on next page ...

CCTG Approved TRIALS

11:10 am	PNC.1 InPACT: International Penile Advanced Cancer Trial	J. Crook
	PR.20 Phase 3 Trial of Local Ablative Therapy or Not for Hormone Sensitive Oligometastatic Prostate Cancer	P. Cheung/T. Niazi
	REC.4 A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)	A. Kapoor
	BLC.3 (SWOG S1602): A Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer.	W. Kassouf
	BL.13 A Randomized Phase II Trial Assessing Trimodality Therapy With Or Without Adjuvant Durvalumab To Treat Patients With Muscle-Invasive Bladder Cancer	W. Kassouf

12:00 pm LUNCH

New trial proposals

1:30 pm	Concept Title: S1802 "Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (surgery or radiation) of the Primary Tumor in Metastatic Prostate Cancer"	K. Chi
	International Rare Cancer Initiative/CRUK Southampton Clinical Trials Unit: non-TCC of the bladder or urotelial tract utilizing immunotherapy	S. North
	Concept Title: A031702 "Phase II study of Cabozantinib in combination with Nivolumab and Ipilimumab in rare genitourinary tumors	C. Kollmansberger
	Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours	C. Kollmansberger
	Darolutamide to Augment Standard Therapy for Localized High-Risk Cancer of the Prostate (DASLHiCaP).	T. Niazi

2:15 pm GU DSC IDENTIFICATION AND PRIORITIZATION

1. Progress against strategic priorities defined for the CCSRI grant.
2. Priority tumour and patient populations over the next 3-5 years.
3. Primary areas of focus for the group in these tumour and patient populations over the next 3-5 years in terms of:
 - treatment modalities
 - targets
 - agents

3:00 pm Meeting Adjourned

3:00 pm – 4:00 pm Trial Development Group CLOSED